Labcorp Holdings Inc. — News

LH heads into Q2 earnings results with expectations for higher revenues and EPS, as diagnostics, specialty testing and new collaborations drive momentum.

zacks.com - 2026-07-22 09:41:07

Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-07-21 13:11:05

California Public Employees Retirement System decreased its position in Labcorp Holdings Inc. (NYSE: LH) by 8.6% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 195,176 shares of the medical research company's stock after selling 18,270 shares during the quarter. California Public Employees

defenseworld.net - 2026-07-21 03:53:49

D.A. Davidson and CO. increased its holdings in shares of Labcorp Holdings Inc. (NYSE: LH) by 17.9% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,575 shares of the medical research company's stock after acquiring an additional 2,824 shares

defenseworld.net - 2026-07-19 04:25:49

Labcorp remains a buy consideration, leveraging a successful rollup strategy in a fragmented laboratory testing industry for steady, predictable growth. Automation is driving cost reductions in LH's operations. That cost reduction helps offset healthcare pricing pressures. With a larger scale, LH now targets single-digit growth and a total return around 10%, prioritizing predictability over rapid expansion.

seekingalpha.com - 2026-07-16 03:02:16

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com - 2026-07-13 10:40:27

BURLINGTON, N.C., July 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

prnewswire.com - 2026-07-09 17:05:00

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-07-07 10:51:09

Investors with an interest in Medical Services stocks have likely encountered both Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com - 2026-07-01 12:40:29

BURLINGTON, N.C., June 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on Thursday, July 30, 2026.

prnewswire.com - 2026-06-30 16:15:00

LH expands specialty testing, acquisitions and AI initiatives to drive growth, but macro pressures and currency headwinds could weigh on results.

zacks.com - 2026-06-25 12:56:09

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-06-25 10:41:14

First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling Meets screening guidelines from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN) BURLINGTON, N.C. and ST. LOUIS, June 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal cancer (CRC) screening approved by the U.S. Food and Drug Administration (FDA).

prnewswire.com - 2026-06-22 07:00:00

Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?

zacks.com - 2026-06-15 12:41:09

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-06-08 10:51:19

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-06-05 10:40:45

Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-03 14:22:22

Labcorp joins a national CRC trial as exclusive genetic testing provider, expanding Invitae-based testing and supporting cancer research.

zacks.com - 2026-06-01 10:16:25

Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer PR Newswire BURLINGTON,

gurufocus.com - 2026-05-29 08:00:00

Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical impact of broader genetic testing in colorectal cancer care BURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC).

prnewswire.com - 2026-05-29 07:00:00

New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment BURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy.

prnewswire.com - 2026-05-28 07:00:00

Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?

zacks.com - 2026-05-27 12:41:13

BURLINGTON, N.C., May 27, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET.

prnewswire.com - 2026-05-27 08:00:00

Labcorp (LH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

zacks.com - 2026-05-22 13:01:13

LH gains from specialty testing growth, acquisitions and AI initiatives, but currency swings and macro pressures remain risks.

zacks.com - 2026-05-22 11:31:22

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-05-20 10:40:25

MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experience Leverages OpenAI models designed to help users understand their results, ask questions and identify patterns over time BURLINGTON, N.C., May 20, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of MyLabcorp ™ , an AI-powered mobile app that brings together lab results, AI-enabled features and clinical guideline-based content in a secure, personalized mobile experience.

prnewswire.com - 2026-05-20 07:00:00

Labcorp's full test menu will be available through Epic's Aura platform Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through Aura Collaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide BURLINGTON, N.C., May 12, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems.

prnewswire.com - 2026-05-12 07:00:00

Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?

zacks.com - 2026-05-08 12:41:08

Labcorp (LH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

zacks.com - 2026-05-06 10:56:13

Labcorp's shares rise after Q1 beats on earnings and revenues, with growth across segments and a higher 2026 outlook signaling continued momentum.

zacks.com - 2026-04-30 13:55:21

Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-04-30 12:41:59

Labcorp Holdings (NYSE:LH) shares are up, up 1.46%, on Thursday as the company reported strong first-quarter results and raised its full-year guidance.

benzinga.com - 2026-04-30 12:05:31

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-04-30 10:40:36

The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-04-30 10:36:02

Labcorp Holdings (LH) came out with quarterly earnings of $4.25 per share, beating the Zacks Consensus Estimate of $4.09 per share. This compares to earnings of $3.84 per share a year ago.

zacks.com - 2026-04-30 09:05:28

Labcorp raised its full-year profit and revenue forecast on Thursday after posting quarterly results above expectations as demand for ​diagnostic testing remained steady.

reuters.com - 2026-04-30 08:04:09

Q1 2026 revenue was $3.54 billion. The revenue estimate was $3,504.54 million.Diluted EPS was $3.35. The EPS estimate was $3.09.Adjusted EPS was $4.25, up 10.6

gurufocus.com - 2026-04-30 07:13:00

Results from Operations for first quarter 2026 versus first quarter 2025: Revenue: $3.54 billion vs. $3.35 billion, up 5.8% Diluted EPS: $3.35 vs.

prnewswire.com - 2026-04-30 06:50:00

Beyond analysts' top-and-bottom-line estimates for Labcorp (LH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.

zacks.com - 2026-04-29 10:15:45

Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-28 11:06:28

Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-23 11:04:05

BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®.i KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.ii Helping Patients Access Critical New Treatment Options Approximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, and many develop resistance to platinum-based chemotherapy, leading to limited treatment options and poor survival outcomes.

prnewswire.com - 2026-04-22 07:00:00